Nusinersin (Spinraza), an approved drug for SMA, works by modulating the splicing of the SMN2 gene, which facilitates the integration of exon 7 into the mRNA, thus enhancing full-length SMN protein production in the central nervous system [29]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.